Yezan Munther Haddadin insider trades

Open-market stock purchases and sales by Yezan Munther Haddadin, Director at Outlook Therapeutics, Inc, from SEC Form 4 filings since Oct 31, 2017.

Track record: 13% of 8 scored buys are up 5% or more since purchase, averaging -37%.

Recent trades

DateStockTradeValue
Jun 2, 2026OTLK Outlook Therapeutics, IncBought$24.1K
May 26, 2026OTLK Outlook Therapeutics, IncBought$15K
Oct 3, 2025OTLK Outlook Therapeutics, IncBought (not open market)—

Companies traded

  • OTLK Outlook Therapeutics, Inc: 8 buys, last Jun 2, 2026
  • ONS Oncobiologics, Inc: other filings, last Oct 31, 2017

Get free alerts when Yezan Munther Haddadin files a new trade →